This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Tumor microenvironment antigens
Seminars in Immunopathology Open Access 29 September 2022
-
Targeting immune checkpoints in hematological malignancies
Journal of Hematology & Oncology Open Access 12 August 2020
-
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Seminars in Immunopathology Open Access 10 September 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Campbell PJ, Green AR . The myeloproliferative disorders. N Engl J Med 2006; 355: 2452–2466.
Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A . Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356–1363.
Skov V, Riley CH, Thomassen M, Larsen TS, Jensen MK, Bjerrum OW et al. Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma 2013; 54: 2269–2273.
Parker BS, Rautela J, Hertzog PJ . Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 2016; 16: 131–144.
Silver RT, Kiladjian J-J, Hasselbalch HC . Interferon and the treatment of polycythaemia vera, essential thrombocytemia and myelofibrosis. Exp Hematol 2013; 6: 1–10.
Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L et al. Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. Eur J Haematol 2016; 97: 83–92.
Xiong Z, Yan Y, Liu E, Silver RT, Verstovsek S, Yang F et al. Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. Clin Immunol 2007; 122: 279–287.
Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Ph D et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.
Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T . Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14: 135–146.
Rammensee H-G, Bachmann J, Emmerich N, Bachor OA, Stevanovic S . SYFPEITHI: database for MHC ligands and peptide motifs. Available at: www.syfpeithi.de (accessed 30 October 2014).
Munir S, Andersen GH, Met Ö, Donia M, Frøsig TM, Larsen SK et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res 2013; 73: 1764–1776.
Moodie Z, Price L, Gouttefangeas C, Mander a, Janetzki S, Löwer M et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010; 59: 1489–1501.
Quentmeier H, MacLeod RaF, Zaborski M, Drexler HG . JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006; 20: 471–476.
Met Ö, Balslev E, Flyger H, Svane IM . High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res Treat 2011; 125: 395–406.
Jedidi A, Marty C, Oligo C, Jeanson-Leh L, Ribeil JA, Casadevall N et al. Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood 2009; 114: 1842–1851.
Acknowledgements
We thank laboratory technician Merete Jonassen for outstanding help with the experiments and for helping MOH to perform the assays. This study was supported in part by grant from Danish Cancer Society to HCH (grant number R90-A6143-14-S2).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
MOH, HCH and MHA have filed a patent regarding the JAK2V617F mutation as a target for cancer immune therapy. The patent has been transferred to University Hospital Zealand, Zealand Region and Copenhagen University Hospital at Herlev, Capital Region according to Danish Law concerning inventions made at public research institutions. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Holmström, M., Hjortsø, M., Ahmad, S. et al. The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms. Leukemia 31, 495–498 (2017). https://doi.org/10.1038/leu.2016.290
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.290
This article is cited by
-
Tumor microenvironment antigens
Seminars in Immunopathology (2023)
-
Identification of neoantigens for individualized therapeutic cancer vaccines
Nature Reviews Drug Discovery (2022)
-
A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor
International Journal of Hematology (2021)
-
Targeting immune checkpoints in hematological malignancies
Journal of Hematology & Oncology (2020)
-
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Seminars in Immunopathology (2019)